Patients hospitalized for acute heart failure (AHF) differ with respect of many clinical characteristics which may influence their prognosis and response to treatment. We have assessed possible differences in the effects of serelaxin on dyspnoea relief, 60 Day outcomes and 180 Day mortality across patient subgroups in the RELAX-AHF trial.
Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF
METRA, Marco;
2013-01-01
Abstract
Patients hospitalized for acute heart failure (AHF) differ with respect of many clinical characteristics which may influence their prognosis and response to treatment. We have assessed possible differences in the effects of serelaxin on dyspnoea relief, 60 Day outcomes and 180 Day mortality across patient subgroups in the RELAX-AHF trial.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
RELAX AHF Subgroups_EHJ_2013.pdf
solo utenti autorizzati
Tipologia:
Documento in Post-print
Licenza:
PUBBLICO - Pubblico con Copyright
Dimensione
999.39 kB
Formato
Adobe PDF
|
999.39 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
